Glycopeptide Utilizing Patents (Class 514/20.9)
-
Publication number: 20120094933Abstract: Derivatives of bladder epithelial antiproliferative factor and methods of using them are disclosed. In specific embodiments, the glycopeptide compositions are useful for the treatment and/or prevention of medical conditions, including cancer. In other embodiments, there are compositions and methods related to treatment of bladder conditions. In particular embodiments, the glycopeptide comprises D-pipecolic acid or L-pipecolic acid.Type: ApplicationFiled: August 18, 2009Publication date: April 19, 2012Inventors: Christopher Michejda, Maria Michejda, Susan K. Keay, Zoltan Szekely, Piotr Kaczmarek
-
Publication number: 20120094934Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TNFR2.Type: ApplicationFiled: June 24, 2010Publication date: April 19, 2012Applicant: OPKO CuRNA, LLCInventors: Joseph Collard, Olga Khorkova Sheman
-
Publication number: 20120093798Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.Type: ApplicationFiled: August 19, 2008Publication date: April 19, 2012Applicant: MIDWESTERN UNIVERSITYInventor: Anil Gulati
-
Publication number: 20120082653Abstract: Methods of treating a lysosomal storage disorder and methods of increasing cellular uptake of a lysosomal enzyme using ?2 agonists or therapeutic agents that increase expression of receptors for a lysosomal enzyme.Type: ApplicationFiled: October 4, 2011Publication date: April 5, 2012Applicant: Duke UniversityInventor: Dwight D. KOEBERL
-
Publication number: 20120082672Abstract: It is disclosed here that synaptotagmin I (syt I) and synaptotagmin II (syt II) are the cellular receptors for botulinum neurotoxin B (BoNT/B) that mediate the cellular entry and toxicity of BoNT/B. The BoNT/B binding domains of syt I and II are also disclosed. While syt I needs gangliosides for BoNT/B binding, syt II can bind to BoNT/B in the absence of gangliosides. Various nucleic acids and polypeptides that relate to the BoNT/B binding domain of syt I or II are disclosed. Further disclosed are methods of reducing BoNT/B toxicity, methods of identifying agents that can block the binding between BoNT/B and syt I or II, methods of identifying agents that can bind to the BoNT/B binding domain of syt I or II, methods of detecting BoNT/B or Clostridium botulinum and kits for use thereof.Type: ApplicationFiled: October 26, 2011Publication date: April 5, 2012Inventors: Edwin Raymond Chapman, Min Dong
-
Publication number: 20120070427Abstract: The present invention provided for a novel process of forming silk fibroin gels, and controlling the rate of ?-sheet formation and resulting hydrogelation kinetics, by vortex treatment of silk fibroin solution. In addition, the vortex treatment of the present invention provides a silk fibroin gel that may be reversibly shear-thinned, enabling the use of these approach for precise control of silk self-assembly, both spatially and temporally. Active agents, including biological materials, viable cells or therapeutic agents, can be encapsulated in the hydrogels formed from the processes, and be used as delivery vehicles. Hence, the present invention provide for methods for silk fibroin gelation that are useful for biotechnological applications such as encapsulation and delivery of active agents, cells, and bioactive molecules.Type: ApplicationFiled: June 1, 2010Publication date: March 22, 2012Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Tuna Yucel
-
Publication number: 20120070474Abstract: A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate.Type: ApplicationFiled: November 29, 2011Publication date: March 22, 2012Applicants: SUMALOGIC, INC., SUMITOMO BAKELITE COMPANY, LTD.Inventors: Mitsutaka MATSUMOTO, Sumio SHIBAHARA, Takayuki MATSUMOTO, Kanehisa YOKOYAMA, Sohei FUNAOKA, Daisuke MASUDA, Michael Patrick COLEMAN, Dominic ZICHI
-
Publication number: 20120065149Abstract: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.Type: ApplicationFiled: September 7, 2011Publication date: March 15, 2012Inventors: Iontcho R. Vlahov, Christopher P. Leamon, Matthew A. Parker, Stephen J. Howard, Hari Krishna Santhapuram, Apparao Satyam, Joseph Anand Reddy
-
Publication number: 20120064048Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors.Type: ApplicationFiled: May 18, 2010Publication date: March 15, 2012Applicant: OPKO CuRNA, LLCInventors: Joseph Collard, Olga Khorkova Sherman
-
Publication number: 20120064127Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a) a lipid fraction comprising at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdenum, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: ApplicationFiled: November 11, 2011Publication date: March 15, 2012Applicant: N.V.NUTRICIAInventor: Robert J.J. Hageman
-
Publication number: 20120058955Abstract: The invention concerns decorin for increasing muscle mass, particularly in the treatment of muscular dystrophies.Type: ApplicationFiled: March 18, 2010Publication date: March 8, 2012Applicant: Association Francaise contre les MyopathiesInventors: Antoine Kichler, Daniel Scherman
-
Patent number: 8129348Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.Type: GrantFiled: October 14, 2008Date of Patent: March 6, 2012Assignee: Cell Therapeutics, Inc.Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
-
Publication number: 20120052077Abstract: The present invention relates to the management of vaginal health. In particular, the present invention relates to pharmaceutical compositions, and methods of use thereof, for treating diseases associated with compromised boundary lubrication at the vaginal epithelium.Type: ApplicationFiled: January 13, 2010Publication date: March 1, 2012Inventors: Edward R. Truitt, III, Benjamin Sullivan, David Sullivan
-
Patent number: 8124073Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: January 8, 2008Date of Patent: February 28, 2012Assignee: Genzyme CorporationInventor: James Stefano
-
Publication number: 20120046236Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tristetraproline (TTP), in particular, by targeting natural antisense polynucleotides of Tristetraproline (TTP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TTP.Type: ApplicationFiled: May 6, 2010Publication date: February 23, 2012Applicant: OPKO CURNA LLCInventors: Joseph Collard, Olga Khorkova Sherman
-
Publication number: 20120045430Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.Type: ApplicationFiled: August 15, 2011Publication date: February 23, 2012Inventors: Dan Luo, Yougen Li
-
Publication number: 20120046220Abstract: The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same.Type: ApplicationFiled: September 23, 2011Publication date: February 23, 2012Inventors: Hailiang Chen, Andrew Xian Chen, Dushyanth Surakanti, Franklin Okumu
-
Publication number: 20120046235Abstract: Conjugates of an active substance and hydroxyalkyl starch (HAS) are provided herein. The active substance and the HAS are linked by a chemical moiety having a structure according to formula (I) wherein Y is O or S, and X is SH or (F). The conjugate has a structure according to formula (IV) wherein HAS? is a residue of HAS or a derivative thereof linked to the thioester group, and AS? is a residue of the active substance or derivative thereof linked to the alpha-X beta-amino group; or a structure according to formula (V) wherein HAS? is a residue of HAS or derivative thereof linked to the alpha-X beta-amino group, and AS? is a residue of the active substance or derivative thereof linked to the thioester group, and wherein the group —(C?Y) is derived from the thioester group —(C?Y)—S—R? and the group HN—CH—CH2—X is derived from the alpha-X beta amino group.Type: ApplicationFiled: September 8, 2006Publication date: February 23, 2012Inventors: Nobert Zander, Ronald Frank
-
Publication number: 20120039801Abstract: Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide—Antibody Fc domain fusion proteins and methods of their use are disclosed.Type: ApplicationFiled: December 7, 2009Publication date: February 16, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20120039843Abstract: The present invention relates to conjugates of a polypeptide and an oligosaccharide, wherein the polypeptide is conjugated to at least one oligosaccharide-spacer residue, the oligosaccharide being a synthetic sulfated oligosaccharide comprising 4-18 monosaccharide units and per se having affinity to antithrombin III and the spacer being a bond or an essentially pharmacologically inactive flexible linking residue, or a pharmaceutically acceptable salt thereof. The conjugates of the invention have improved pharmacokinetic properties when compared to the original polypeptides (i.e. the corresponding non-conjugated polypeptides per se).Type: ApplicationFiled: September 8, 2011Publication date: February 16, 2012Applicant: N.V. OrganonInventors: Ebo Sybren Bos, Martin De Kort, Meertinus Jan Smit, Constant Adriaan Anton Van Boeckel
-
Publication number: 20120035115Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.Type: ApplicationFiled: September 23, 2009Publication date: February 9, 2012Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Takeshi Yamada, David Butler, K. Narayanannair Jayaprakash, Muthusamy Jayraman, Shigeo Matsuda, Rajendra K. Pandey, Chang Geng Peng
-
Publication number: 20120034294Abstract: Liposomes of constrained particle size are prepared by substantially continuously mixing substantially continuously flowing streams of water, and of an organic solvent contain lipid(s) capable of forming liposomes, and cooling the mixture so liposomes form, the ratio of the flow rate of the stream of water to the flow rate of the stream of organic solvent, and the rate of cooling of said mixture, being controlled so as to obtain a preparation of liposomes such that at least about 90% of the liposomes are of a particle size less than about 200 nm.Type: ApplicationFiled: December 17, 2009Publication date: February 9, 2012Applicant: ONCOTHYREON, INC.Inventors: Robert A. Dupuit, William J. Reilley
-
Publication number: 20120034162Abstract: A composition and method is described for intracellular delivery of fullerene containing peptides. The composition and method involve fullerene-substituted phenylalanine as part of a peptide based delivery system. The presence of a fullerene-substituted amino acid in a peptide is found to alter the intracellular transport properties of the peptide.Type: ApplicationFiled: March 30, 2007Publication date: February 9, 2012Applicant: William March Rice UniversityInventors: Andrew R. Barron, Jianzhong Yang, Jianhua Yang, Kuan Wang, Jonathan Driver
-
Publication number: 20120028911Abstract: The present technology relates to isolated MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides encoding the same. The MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides can be used to treat gastrointestinal tract diseases and disorders. Also described herein are pharmaceutical compositions comprising MUC17, Muc3 or MUC3 derived polypeptides and/or polynucleotides encoding the same alone or in combination along with a pharmaceutically acceptable carrier, diluent or excipient for the treatment of gastrointestinal disorders and diseases, including, irritable bowel disease and its associated colitides, for example, Crohn's Disease.Type: ApplicationFiled: April 29, 2011Publication date: February 2, 2012Applicant: MuciMed, Inc.Inventors: Ronald J. Shebuski, Samuel B. Ho, Laurie Shekels, Robert L. Heinrikson
-
Publication number: 20120021987Abstract: The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGFlike domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids.Type: ApplicationFiled: February 7, 2011Publication date: January 26, 2012Applicant: MuciMed, Inc.Inventors: Samuel B. Ho, Laurie L. Shekels
-
Publication number: 20120021042Abstract: A method for preparing amphoteric liposomes loaded with polyanionic active agent as cargo, characterised by admixing an aqueous solution of said polyanionic active agent and an alcoholic solution of one or more amphiphiles and buffering said admixture to an acidic pH, said one or more amphiphiles being susceptible of forming amphoteric liposomes at said acidic pH, thereby to form such amphoteric liposomes in suspension encapsulating said active agent under conditions such that said liposomes form aggregates, and thereafter treating said suspension to dissociate said aggregates. Also disclosed are nucleic acid loaded amphoteric liposomes produced in accordance with the method, wherein said nucleic acids are oligonucleotides and said liposomes are multilamellar.Type: ApplicationFiled: March 16, 2007Publication date: January 26, 2012Inventors: Steffen Panzner, Gerold Endert, Una Rauchhaus, Natalie Herzog, Claudia Muller
-
Patent number: 8101196Abstract: The invention includes a medical hydrogel made from polymerized polysaccharide macromers. The macromers are preferably polysaccharides decorated with polymerizable groups, for example, methacrylates. The macromers may also be made into polymers of at least two macromers polymerized together. These polymers are preferably multi-armed or high-molecular weight and used for medical uses, for example, making coatings on medical devices. Macromers of N-vinylpyrrolidone are also disclosed herein.Type: GrantFiled: June 25, 2002Date of Patent: January 24, 2012Assignee: BioInteractions, Ltd.Inventors: Ajay K. Luthra, Shivpal S. Sandhu, John O. Hudson
-
Patent number: 8101575Abstract: Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.Type: GrantFiled: March 2, 2010Date of Patent: January 24, 2012Assignee: Theravance, Inc.Inventor: Michael R. Leadbetter
-
Publication number: 20120015026Abstract: The present invention relates generally to the fields of molecular biology, medicine, oncology, and delivery of therapeutic compounds. In particular, the present invention relates to pharmaceutical compositions containing a hydrophobic drug substance and an inhibitory nucleic acid molecule, such as short interfering RNA (siRNA), in a single drug delivery system, as well as a process for making and a process for administering the same.Type: ApplicationFiled: March 24, 2010Publication date: January 19, 2012Inventors: Giancarlo Francese, Michael Keller
-
Publication number: 20120014964Abstract: Present inventions demonstrates that alpha synuclein toxicity such as ?-synuclein mediated cell death, alpha synuclein induced reactive oxygen species (ROS) in a cell requires the proapoptotic endonuclease G and that the deletion of the endonuclease G or suppressing of the endonuclease G apoptotic pathway attenuates or counteracts such alpha synuclein toxicity. The present invention compositions and methods for inhibition of ?-synuclein toxicity. The inhibiting ?-synuclein toxicity can be used in methods of treatment of synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and multiple system atrophy (MSA) and the manufacture of medicaments for such treatment.Type: ApplicationFiled: August 7, 2008Publication date: January 19, 2012Inventors: Veerle Baekelandt, Sabrina Buettner, Frank Madeo, Joris Winderickx
-
Publication number: 20120010156Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like (1) homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like (1) homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of (DLK1).Type: ApplicationFiled: March 16, 2010Publication date: January 12, 2012Inventors: Joseph Collard, Olga Khorkova Sherman, Carios Coito
-
Publication number: 20120009123Abstract: The invention provides compositions and methods for delivering a therapeutic or diagnostic agent to a disease site in a mammal, the method comprising administering to the mammal a therapeutically or diagnostically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises the therapeutic or diagnostic agent coupled to an albumin binding peptide and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 7, 2009Publication date: January 12, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20120010155Abstract: The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTIII that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.Type: ApplicationFiled: December 29, 2010Publication date: January 12, 2012Inventors: Hendrikus Antonius Cornelis Bakker, Dionisius Elisabeth Antonius Florack, Hendrik Jan Bosch
-
Patent number: 8092780Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.Type: GrantFiled: October 31, 2008Date of Patent: January 10, 2012Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Philip O. Livingston, Govindaswami Ragupathi, Samuel J. Danishefsky
-
Publication number: 20120004181Abstract: The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a plurality of HerPBK10 combined with siRNA form a nanoparticle.Type: ApplicationFiled: July 22, 2011Publication date: January 5, 2012Applicant: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. Medina-Kauwe
-
Publication number: 20120004183Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.Type: ApplicationFiled: June 23, 2011Publication date: January 5, 2012Applicant: The Scripps Research InstituteInventors: Alexander Deiters, T. Ashton Cropp, Jason W. Chin, J. Christopher Anderson, Peter G. Schultz
-
Publication number: 20120004184Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nu-clear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.Type: ApplicationFiled: March 16, 2010Publication date: January 5, 2012Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
-
Publication number: 20120003191Abstract: The present disclosure includes methods and compositions for treating any condition or disorder that benefits from activation of the Akt signaling pathway. These methods and compositions involve the use of valproic acid, derivatives, analogs and compositions including the same for treating muscular disorders, such as muscular dystrophy.Type: ApplicationFiled: December 18, 2009Publication date: January 5, 2012Inventors: Dean J. Burkin, Praveen B. Gurpur, Stephen J. Kaufman
-
Publication number: 20110319341Abstract: A penetrating composition can include an active agent that has an activity that is either beneficial for plants or controls pests. The composition can also include a penetrant that is present in an effective amount for carrying the at least one active agent into or through a medium, the medium being at least one of a plant, soil, or pest. Also, penetrating composition can be used for increasing the permeation of an active agent in an animal. The composition includes an active agent having an activity that is beneficial for an animal. Also, the composition includes a penetrant selected from the group consisting of biosurfactants, glycolipids, lipopeptides, favolipids, lipoproteins, phospholipids, lipopolysaccharide-protein complexes, polysaccharide-protein-fatty acid complexes, and combinations thereof. A biosurfactant composition can include an effective amount of a biosurfactant for controlling a pest, preserving a plant cutting, or reducing effects of environmental stress on a plant.Type: ApplicationFiled: July 13, 2011Publication date: December 29, 2011Inventors: Salam M. Awada, Mohamed M. Awada, Rex S. Spendlove
-
Publication number: 20110318416Abstract: A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the reaction mixture of 6 or less. The composition may include a release agent for the controlled release of the bioactive agent from the composition.Type: ApplicationFiled: September 8, 2011Publication date: December 29, 2011Applicant: ROYER BIOMEDICAL, INC.Inventor: Garfield P. ROYER
-
Publication number: 20110318382Abstract: An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5? exocyclic carbon of an adjacent subunit, (ii) is capable of uptake by monocytes, lymphocytes, and dendritic cells in a mammalian subject, (iii) contains between 10-40 nucleotide bases, and (iv) has a base sequence effective to hybridize to at least 12 contiguous bases of a target sequence contained in an exon-2 or exon-4 slice site region of human IL-10 pre-mRNA.Type: ApplicationFiled: June 22, 2011Publication date: December 29, 2011Applicant: AVI BIOPHARMA, INC.Inventors: Dan V. Mourich, Patrick L. Iversen
-
Publication number: 20110319342Abstract: A biologically inactivated cell-specifically effective molecule for biologically inactive transfection into a target cell to inhibit expression of genes in the target cell after biological activation of the molecule, by bonding to mRNA and with the formation of a RISC complex, the biologically inactivated cell-specifically effective molecule comprising siRNA coupled with at least one peptide via a linker which remains at the siRNA after biological activation of the molecule, the linker comprising an amino Cn linker wherein n is an integer of 1-6. Kits include the molecule or the constituents thereof and transfection reagents in ampoules and injection equipment for injecting mixtures of the ampoule contents into a medium containing a target cell.Type: ApplicationFiled: March 12, 2010Publication date: December 29, 2011Inventors: Tobias Poehlmann, Diana Imhof, Sandra Koehn
-
Publication number: 20110311530Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.Type: ApplicationFiled: August 19, 2011Publication date: December 22, 2011Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
-
Publication number: 20110311512Abstract: Compositions and methods for the detection and treatment of neurological disorders, including ASD, are provided.Type: ApplicationFiled: November 16, 2009Publication date: December 22, 2011Inventors: Hakon Hakonarson, Brett Abrahams, Maja Bucan, Dan Geschwind, Edward Herman, Kai Wang
-
Publication number: 20110305770Abstract: The present invention relates to polymer conjugated releasable lipids and nanoparticle compositions containing the same for the delivery of nucleic acids and methods of modulating gene expression using the same. In particular, this invention relates to releasable polymeric lipids containing an acid-labile linker based on a ketal or acetal-containing linker, or an imine-containing linker.Type: ApplicationFiled: November 17, 2009Publication date: December 15, 2011Applicant: ENZON PHARMACEUTICALS, INC.Inventors: Hong Zhao, Weili Yan, Lianjun Shi, Dechun Wu
-
Patent number: 8076299Abstract: It is an object of the present invention to provide a novel method for producing a peptide thioester. In the present invention, general peptide synthesis is performed on a solid-phase resin, carboxylic acid obtained after cutout is allowed to react with p-toluenesulfonyl isocyanate, and then the reaction product is alkylated, and is reacted with thiol. Thus, peptide thioester is simply synthesized under mild conditions.Type: GrantFiled: October 25, 2006Date of Patent: December 13, 2011Assignee: RikenInventors: Shino Manabe, Yukishige Ito, Tomoyuki Sugioka
-
Publication number: 20110301097Abstract: The present invention is directed toward a composition for widespread distribution, systemic expression and sustained delivery of a therapeutic agent and to a process for administration of a therapeutic agent via a natural gastrointestinal pathway. More particularly, the invention discloses a composition for the administration of oral gene therapy and a process for its production and use.Type: ApplicationFiled: August 17, 2011Publication date: December 8, 2011Inventors: Gonzalo Hortelano, Andrew Gomez Vargas
-
Publication number: 20110300120Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.Type: ApplicationFiled: December 11, 2009Publication date: December 8, 2011Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
-
Publication number: 20110300245Abstract: The invention is a new unique, palatable, topical, anti-inflammatory and analgesic designed around a specific set of painful conditions, with specifically designated applications, using a different methodology and formulation, with no NSAIDS, steroids or salicylites, than the prior art for this specific set of painful conditions. Thus creating an improved dissimilar system, preventing the prior arts required invasive, costly and inefficient medical procedures, and with a unique lack of negative effects when compared with the prior art. Thereby, facilitating an anti-inflammatory analgesic effect to areas correlating or relating to the trigeminal nervous system, both intraoral and extraoral.Type: ApplicationFiled: June 3, 2010Publication date: December 8, 2011Inventor: Wendy Lou Marshall
-
Publication number: 20110294736Abstract: The present invention provides a method and composition for the treatment and prevention of an autoimmune disease such a multiple sclerosis which is mediated by autoreactive T cells. The administration of a NOD-1 agonist is shown to mediate an anti-inflammatory immune response. NOD-1 agonists suitable for use in the methods and compositions of the invention include diaminopimelic acid (DAP)-containing muropeptide compounds such as Tri-DAP and M-TriDAP.Type: ApplicationFiled: December 22, 2009Publication date: December 1, 2011Applicant: THE PROVOST, FELLOWS AND SCHOLARS OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINInventors: Kingston Mills, Sarah Higgins